Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Solnatide in moderate-to-severe ARDS
NCT03567577Phase 2Completed
- Sponsor
- APEPTICO
- Start
- May 2018
- Primary completion
- Dec 2024
- Modality
- Modified Peptides, Native Peptides
- Countries
- 2
01
Overview
A Phase 2 trial of solnatide in acute respiratory distress syndrome (ARDS), sponsored by APEPTICO. Started May 2018; status: completed.
02
Drugs
solnatide
03
Conditions
acute respiratory distress syndrome (ARDS)
Beyond the preview
Go deeper on NCT03567577.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03567577.